Dyne Therapeutics announces FDA Fast Track designation for DYNE-101, targeting myotonic dystrophy type 1 with potential accelerated approval in 2026. Dyne Therapeutics has announced that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback